Department of Biochemistry and Clinical Chemistry, Faculty of Medicine, University of Kelaniya, Ragama 11010, Sri Lanka.
Aspiration Academy, Osmanpura, Aurangabad 431005, Maharashtra, India.
J Med Chem. 2022 Mar 10;65(5):3706-3728. doi: 10.1021/acs.jmedchem.1c01737. Epub 2022 Feb 22.
Glucose, the primary substrate for ATP synthesis, is catabolized during glycolysis to generate ATP and precursors for the synthesis of other vital biomolecules. Opportunistic viruses and cancer cells often hijack this metabolic machinery to obtain energy and components needed for their replication and proliferation. One way to halt such energy-dependent processes is by interfering with the glycolytic pathway. 2-Deoxy-d-glucose (2-DG) is a synthetic glucose analogue that can inhibit key enzymes in the glycolytic pathway. The efficacy of 2-DG has been reported across an array of diseases and disorders, thereby demonstrating its broad therapeutic potential. Recent approval of 2-DG in India as a therapeutic approach for the management of the COVID-19 pandemic has brought renewed attention to this molecule. The purpose of this perspective is to present updated therapeutic avenues as well as a variety of chemical synthetic strategies for this medically useful sugar derivative, 2-DG.
葡萄糖是 ATP 合成的主要底物,在糖酵解过程中被分解代谢,生成 ATP 和其他重要生物分子合成的前体。机会主义病毒和癌细胞经常劫持这种代谢机制,以获取能量和复制及增殖所需的成分。阻止这种依赖能量的过程的一种方法是干扰糖酵解途径。2-脱氧-D-葡萄糖(2-DG)是一种合成的葡萄糖类似物,可以抑制糖酵解途径中的关键酶。2-DG 在多种疾病和病症中的疗效已经得到了报道,从而证明了它具有广泛的治疗潜力。最近印度批准 2-DG 作为治疗 COVID-19 大流行的一种方法,引起了人们对这种分子的重新关注。本文的目的是介绍该具有医学用途的糖衍生物 2-DG 的最新治疗途径以及各种化学合成策略。